The Case For Kneat

Kneat Gx is a digital validation platform designed for life sciences organizations, offering significant return on investment (ROI) through cost savings and revenue generation. By eliminating paper-based processes, Kneat reduces overhead expenses, labor hours, and travel costs while improving data integrity. Additional cost benefits include more efficient processes, fewer corrective actions, and reduced onsite visits.

Kneat also enhances revenue generation by streamlining validation workflows, accelerating time-to-market, and increasing equipment uptime. These improvements boost productivity, quality, and competitiveness, especially for small-to-medium businesses and contract manufacturing organizations. The platform’s cross-organizational utility enables seamless reuse of validation data across multiple processes, further increasing efficiency.

Implementing Kneat involves upfront costs, such as software licenses and training, but its phased deployment approach minimizes disruption and allows organizations to scale effectively. Merck Sharp & Dohme (MSD) exemplified this strategy by rolling out Kneat across 27 global sites in three stages: a pilot launch, early adopter sites, and a global rollout. This phased strategy enabled MSD to reduce cycle times by over 50% and consolidate processes, enhancing operational efficiency.

Building a business case for Kneat involves calculating ROI using measurable cost savings and revenue gains while aligning the proposal with broader organizational goals, such as digital transformation and quality improvement. Kneat’s ROI calculator and tailored questionnaire assist in demonstrating its value, making it a trusted platform for eight of the world’s top 10 pharma companies. Kneat Gx empowers life sciences organizations to achieve scalable, compliant, and efficient digital validation.